Actively Recruiting
Evaluating Neoadjuvant Botensilimab and Balstilimab Immunotherapy Before Surgery for Advanced Resectable Colorectal Cancer
Led by City of Hope Medical Center · Updated on 2026-10-19
100
Participants Needed
11
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the use of botensilimab and balstilimab, two immunotherapy drugs, given before surgery to treat advanced colorectal cancer that can be surgically removed. This phase II trial focuses on patients with mismatch repair proficient or microsatellite stable colorectal cancer, aiming to see if these drugs can improve disease-free survival and reduce tumor size prior to surgery. The study also investigates safety, pathologic responses, quality of life, and other outcomes. Participants receive botensilimab intravenously on day 1 and balstilimab intravenously on days 1, 15, 29, and 43 if there is no disease progression or unacceptable side effects. Surgery to remove the cancer is performed 5 to 16 weeks after treatment. Throughout the study, patients undergo CT or MRI scans and blood sample collections to monitor tumor response and other biological markers. After treatment and surgery, participants are followed for up to three years with visits at 2 and 4 weeks, then every 3 months for 2 years, and every 6 months for an additional year. Researchers monitor disease-free survival, recurrence, adverse events, quality of life, and the timing of surgery. Blood tests and imaging help assess tumor changes and detect molecular recurrence to better understand long-term outcomes.
CONDITIONS
Brief Title
Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3
Research Team
S
Sebastian Perez
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here